• Consensus Rating: Buy
  • Consensus Price Target: $11.33
  • Forecasted Upside: 1,118.51%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.93
▲ +0.0232 (2.56%)

This chart shows the closing price for IVVD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Invivyd Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVVD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVVD

Analyst Price Target is $11.33
▲ +1,118.51% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Invivyd in the last 3 months. The average price target is $11.33, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 1,118.51% upside from the last price of $0.93.

This chart shows the closing price for IVVD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Invivyd. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/5/2024GuggenheimUpgradeNeutral ➝ Buy$9.00
3/26/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$4.00 ➝ $10.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
1/18/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $15.00
12/19/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$1.00 ➝ $4.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00
5/1/2023HC WainwrightInitiated CoverageBuy$5.00
3/27/2023Morgan StanleyLower TargetUnderweight$2.00 ➝ $1.00
1/24/2023Morgan StanleyLower TargetUnderweight$3.00 ➝ $2.00
9/14/2022Morgan StanleyInitiated CoverageUnderweight$3.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
4/3/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/2/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/31/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/30/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Invivyd logo
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.93
Low: $0.92
High: $0.96

50 Day Range

MA: $0.99
Low: $0.81
High: $1.29

52 Week Range

Now: $0.93
Low: $0.81
High: $5.20

Volume

246,555 shs

Average Volume

635,130 shs

Market Capitalization

$110.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Invivyd?

The following Wall Street sell-side analysts have issued stock ratings on Invivyd in the last year: Guggenheim, HC Wainwright, and Morgan Stanley.
View the latest analyst ratings for IVVD.

What is the current price target for Invivyd?

3 Wall Street analysts have set twelve-month price targets for Invivyd in the last year. Their average twelve-month price target is $11.33, suggesting a possible upside of 1,118.5%. HC Wainwright has the highest price target set, predicting IVVD will reach $15.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $9.00 for Invivyd in the next year.
View the latest price targets for IVVD.

What is the current consensus analyst rating for Invivyd?

Invivyd currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IVVD will outperform the market and that investors should add to their positions of Invivyd.
View the latest ratings for IVVD.

What other companies compete with Invivyd?

How do I contact Invivyd's investor relations team?

Invivyd's physical mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The company's listed phone number is 781-819-0080 and its investor relations email address is [email protected]. The official website for Invivyd is adagiotx.com. Learn More about contacing Invivyd investor relations.